Reuters logo
MARKET EYE-Glenmark gains on USFDA nod for diarrhoea drug
January 1, 2013 / 8:12 AM / 5 years ago

MARKET EYE-Glenmark gains on USFDA nod for diarrhoea drug

* Shares in Glenmark Pharmaceuticals gain 2.5 percent
after U.S. health regulators approved Salix Pharmaceuticals
Ltd's drug to treat diarrhoea in HIV/AIDS patients on
qantiretroviral therapy, a combination of medicines used to
treat HIV infection. 
* Glenmark will be the active pharmaceutical ingredients
supplier for the drug to Salix in regulated markets.
* An international arbitrator ruled in August 2012 that Glenmark
Pharmaceuticals has the right to sell its HIV-associated
diarrhoea drug Crofelemer in 140 countries. 
* Edelweiss in a report says, "The overall potential market for
Crofelemer is anticipated at $300 million-$500 million and peak
potential revenue for Glenmark, from API supply, could be $15
million-$20 million per annum."

 ( /;

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below